Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M
Dipartimento di Malattie Infettive e Tropicali, Università La Sapienza, Rome, Italy.
J Viral Hepat. 2003 Mar;10(2):126-33. doi: 10.1046/j.1365-2893.2003.00403.x.
A retrospective multicentre survey was conducted to evaluate, in patients with chronic hepatitis C, the long-term liver histological changes induced by interferon (IFN). A total of 112 patients (mean age 46.4 years) were studied. All patients had received a 6-12-month IFN-alpha course (6-18 MU/week) and had successively undergone clinical, biochemical and virological follow-up for at least 36 months (range: 36-76). In each patient, two liver biopsies had been performed: 1-6 months before treatment and, 12-76 months after its completion. In 87 patients with biochemical and virological sustained response persisting for 12 months after therapy, post-treatment liver necroinflammation and fibrosis mean(+/-SD) scores (Knodell index) were significantly lower than pretreatment scores (2.9 +/- 2.2 vs 6.8 +/- 2.9 and 0.8 +/- 1.0 vs 1.2 +/- 1.1, respectively; P < 0.01). In 25 patients who relapsed within 1 year, necroinflammation and fibrosis post-treatment mean scores were similar to pretreatment scores (7.4 +/- 3.2 vs 6.9 +/- 3.1 and 1.8 +/- 1.3 vs 1.6 +/- 1.2, respectively; P > 0.05). On an individual basis, necroinflammation decreased in 87% of sustained responders but only in 36% of relapsers (P < 0.001), whereas fibrosis decreased in 44% of sustained responders but only in 14% of relapsers (P < 0.001). In sustained responders with biopsies performed 12-23 months (n=34), 24-35 months (n=26) or more than 36 months (n=27) after treatment, a progressive decrease of mean necroinflammatory score was observed (-2.6 +/- 2.1, -4.1 +/- 3.4 and -5.2 +/- 3.7 points, respectively; P < 0.01). A similar pattern was observed in fibrosis score (-0.3 +/- 0.6, -0.3 +/- 0.7 and -0.7 +/- 0.9 points, respectively; P < 0.05). Hence, among chronic hepatitis C patients treated with IFN, those with a 12-month sustained response, unlike those who relapse, have a long-term progressive reduction and, in some cases, a complete regression of liver histological damage.
开展了一项回顾性多中心调查,以评估慢性丙型肝炎患者中干扰素(IFN)诱导的长期肝脏组织学变化。共研究了112例患者(平均年龄46.4岁)。所有患者均接受了为期6 - 12个月的干扰素α疗程(6 - 18 MU/周),并先后接受了至少36个月(范围:36 - 76个月)的临床、生化和病毒学随访。每位患者均进行了两次肝脏活检:治疗前1 - 6个月以及治疗结束后12 - 76个月。在87例治疗后生化和病毒学持续应答持续12个月的患者中,治疗后肝脏坏死炎症和纤维化的平均(±标准差)评分(Knodell指数)显著低于治疗前评分(分别为2.9±2.2对6.8±2.9以及0.8±1.0对1.2±1.1;P<0.01)。在25例1年内复发的患者中,治疗后坏死炎症和纤维化的平均评分与治疗前评分相似(分别为7.4±3.2对6.9±3.1以及1.8±1.3对1.6±1.2;P>0.05)。就个体而言,87%的持续应答者坏死炎症减轻,但复发者中只有36%减轻(P<0.001),而44%的持续应答者纤维化减轻,但复发者中只有14%减轻(P<0.001)。在治疗后12 - 23个月(n = 34)、24 - 35个月(n = 26)或超过36个月(n = 27)进行活检的持续应答者中,观察到平均坏死炎症评分逐渐降低(分别为-2.6±2.1、-4.1±3.4和-5.2±3.7分;P<0.01)。纤维化评分也观察到类似模式(分别为-0.3±0.6、-0.3±0.7和-0.7±0.9分;P<0.05)。因此,在接受干扰素治疗的慢性丙型肝炎患者中,那些有12个月持续应答的患者,与复发患者不同,其肝脏组织学损伤有长期的逐渐减轻,在某些情况下可完全消退。